Drugs / Dianhydrogalactitol
Dianhydrogalactitol
also known as
VAL-083 · 1,2:5,6-dianhdrogalactitol · 1,2:5,6-dianhydrogalactitol · DAG · Dianhidrogalactitol · Dulcitol diepoxide · NSC-132313 · NSC-1323313
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03281681 | Mar 2021 → Mar 2022 | ovarian carcinoma | DelMar Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01478178 | Oct 2011 → Dec 2015 | brain cancer, glioblastoma | Kintara Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03050736 | Dec 2017 → Nov 2021 | brain cancer, glioblastoma | Kintara Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02717962 | Jan 2017 → Dec 2024 | brain cancer, glioblastoma | Kintara Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT03970447 | Jul 2019 → Jun 2028 expected | glioblastoma | Global Coalition for Adaptive Research | Recruiting | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03149575 | Oct 2017 → May 2019 | brain cancer, glioblastoma | DelMar Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT03138629 Background | — | cancer | Kintara Therapeutics, Inc. | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-06-22 | DelMar Pharmaceuticals, Inc. | Results Positive Interim Data on VAL-083 delmarpharma.com ↗
today announced positive interim data from its two Phase 2 trials of VAL-083 for the treatment of glioblastoma multiforme (GBM) demonstrating improved outcomes over current standard of care as both a first-line treatment and for recurrent GBM. |
| 2019-08-13 | DelMar Pharmaceuticals, Inc. | Results Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 delmarpharma.com ↗
Importantly, 16 of the 20 patients enrolled (80%) were still alive as of the August 1, 2019 data cut-off date. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-06-22 | DelMar Pharmaceuticals, Inc. | Positive Interim Data on VAL-083 delmarpharma.com ↗ |
| 2020-03-04 | DelMar Pharmaceuticals, Inc. | Canada Pharmacy Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 delmarpharma.com ↗ |
| 2020-02-19 | DelMar Pharmaceuticals, Inc. | Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors delmarpharma.com ↗ |
| 2019-08-13 | DelMar Pharmaceuticals, Inc. | Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 delmarpharma.com ↗ |
| 2019-07-31 | DelMar Pharmaceuticals, Inc. | DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) delmarpharma.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dianhydrogalactitol | “provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency” NCT03138629 ↗5“Drug: VAL-083, Dianhydrogalactitol” NCT03281681 ↗ “VAL-083 (Dianhydrogalactitol)” NCT01478178 ↗ “VAL-083 (Dianhydrogalactitol)” NCT03050736 ↗ “VAL-083, Dianhydrogalactitol” NCT02717962 ↗ “VAL-083, Dianhydrogalactitol” NCT03149575 ↗ |
| Known as | 1,2:5,6-dianhdrogalactitol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | 1,2:5,6-dianhydrogalactitol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | DAG | “VAL-083 (dianhydrogalactitol; DAG) is a DNA-targeting agent” PMID 41385182 ↗ Dec 2025 |
| Known as | Dianhidrogalactitol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | Dulcitol diepoxide | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | NSC-132313 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | NSC-1323313 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137322 ↗ |
| Known as | VAL-083 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03050736 ↗ |
| Modality | Other / unclassified | “The study drug, dianhydrogalactitol (VAL 083) is a bi-functional N7 DNA alkylating agent” NCT03050736 ↗ |
| Route | Intravenous | “given by intravenous infusion” NCT01478178 ↗ |